CYP2S1: Key Enzyme in Drug Metabolism and Disease (G29785)

Target Name: CYP2S1

NCBI ID: G29785

CYP2S1

CYP2S1: Key Enzyme in Drug Metabolism and Disease

CYP2S1, also known as cytochrome P540 (P540), is a member of the cytochrome P450 subfamily IIS and is responsible for metabolizing a wide variety of drugs, including many statins, antidepressants, and benzodiazepines. It is a cytochrome P450 enzyme that is expressed in many different tissues and organs throughout the body, including the liver, kidney, and fatty tissues.

One of the key functions of CYP2S1 is its role in drug metabolism. It is a potent metabolite generator and has been shown to metabolize a wide variety of drugs, including many statins, antidepressants, and benzodiazepines. CYP2S1 is also known for its role in the production of other metabolites, such as 14-hydroxy-CYP2S1 and 14-nor-9-carboxy-CYP2S1, which are potential biomarkers for drug toxicity and efficacy.

CYP2S1 is also involved in the regulation of cellular processes that are important for drug response. For example, it has been shown to play a role in the regulation of the levels of different proteins in the liver, including the protein transmembrane protein (TMP), which is involved in the absorption and retention of drugs.

In addition to its role in drug metabolism and regulation, CYP2S1 is also a potential drug target. Several studies have suggested that inhibiting CYP2S1 activity may be a promising strategy for treating drug-resistant diseases, such as cardiovascular disease and neurodegenerative disorders.

One approach to inhibiting CYP2S1 activity is through the use of CYP2S1 inhibitors, which are drugs that specifically target the enzyme and prevent it from functioning. These drugs have been shown to be effective in treating a variety of conditions, including drug-resistant hypertension, cardiovascular disease, and neurodegenerative disorders.

Another approach to inhibiting CYP2S1 activity is through the use of CYP2S1 inhibitors that selectively target the enzyme in certain tissues or conditions. For example, some studies have suggested that inhibitors that are specific for CYP2S1 may be more effective than inhibitors that are less specific, as they will have a more targeted and less diffuse effect on the enzyme.

In conclusion, CYP2S1 is a key enzyme in the regulation of drug metabolism and cellular processes, and it has the potential to be a drug target or biomarker for a variety of conditions. Further research is needed to fully understand the role of CYP2S1 in drug response and to develop effective inhibitors for this enzyme.

Protein Name: Cytochrome P450 Family 2 Subfamily S Member 1

Functions: A cytochrome P450 monooxygenase involved in the metabolism of retinoids and eicosanoids (PubMed:12711469, PubMed:21068195). In epidermis, may contribute to the oxidative metabolism of all-trans-retinoic acid. For this activity, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:12711469). Additionally, displays peroxidase and isomerase activities toward various oxygenated eicosanoids such as prostaglandin H2 (PGH2) and hydroperoxyeicosatetraenoates (HPETEs) (PubMed:21068195). Independently of cytochrome P450 reductase, NADPH, and O2, catalyzes the breakdown of PGH2 to hydroxyheptadecatrienoic acid (HHT) and malondialdehyde (MDA), which is known to act as a mediator of DNA damage (PubMed:21068195)

The "CYP2S1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2S1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets